Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances and Challenges in the Diagnosis and Treatment of Urological...
share announcement

Advances and Challenges in the Diagnosis and Treatment of Urological Malignancies (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 771

Special Issue Editors

Dr. Bartosz Małkiewicz

E-Mail Website
Guest Editor
University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Interests: uro-oncology; lymph node metastasis-growth and immune evasion; minimally invasive surgery; radio-guided surgery; prostate cancer; bladder cancer
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Jakub Dobruch

E-Mail Website
Guest Editor
Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, 00-416 Warsaw, Poland
Interests: urologic oncology; molecular diagnostics; endoscopic surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Łukasz Nowak

E-Mail
Guest Editor
University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Interests: uro-oncology; bladder cancer; cancer cell biology; bladder cancer cell cultures; bladder cancer organoids; biomarkers; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue Advances and Challenges in the Diagnosis and Treatment of Urological Malignancies, which has 24 papers published.

The incidence of urological tumors has increased significantly over the past 40 years, and prostate cancer is the second most common malignancy among men. Even if in most cases the initial treatment is curative, a certain number of patients experience a poor course of disease with local or distant recurrence, and require further treatment, which significantly worsens their quality of life.

Over the past two decades, great efforts have been made to improve diagnosis and treatment outcomes. Molecular biomarkers have been investigated and introduced into clinical practice, and new pathological and clinical classifications have been proposed to account for tumor behavior and risk of disease recurrence. At the same time, new surgical and pharmacological approaches have been developed to improve treatment outcomes.

Nevertheless, many issues remain a matter of debate regarding accurate diagnosis, targeted therapy, and multidisciplinary management.

This Special Issue of Cancers will cover all aspects of urological cancers, including original research into advanced imaging, molecular characterization, current and experimental treatment options, and quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Dr. Bartosz Małkiewicz
Prof. Dr. Jakub Dobruch
Dr. Łukasz Nowak
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • bladder cancer
  • upper urinary tract tumors
  • kidney cancer
  • testicular tumors
  • molecular markers
  • lymph node metastasis
  • diagnosis
  • radical treatment
  • systemic treatment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1083 KiB  
Article
“Seeing Is Believing”: Additive Utility of 68Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis
by Joel Chin, Yu Guang Tan, Alvin Lee, Tze Kiat Ng, Ruoyu Shi, Charlene Yu Lin Tang, Sue Ping Thang, Jeffrey Kit Loong Tuan, Christopher Wai Sam Cheng, Kae Jack Tay, Henry Sun Sien Ho, Hung-Jen Wang, Peter Ka-Fung Chiu, Jeremy Yuen-Chun Teoh, Winnie Wing-Chuen Lam, Yan Mee Law, John Shyi Peng Yuen and Kenneth Chen
Cancers 2024, 16(9), 1777; https://doi.org/10.3390/cancers16091777 - 5 May 2024
Viewed by 625
Abstract
Widespread adoption of mpMRI has led to a decrease in the number of patients requiring prostate biopsies. 68Ga-PSMA-11 PET/CT has demonstrated added benefits in identifying csPCa. Integrating the use of these imaging techniques may hold promise for predicting the presence of csPCa [...] Read more.
Widespread adoption of mpMRI has led to a decrease in the number of patients requiring prostate biopsies. 68Ga-PSMA-11 PET/CT has demonstrated added benefits in identifying csPCa. Integrating the use of these imaging techniques may hold promise for predicting the presence of csPCa without invasive biopsy. A retrospective analysis of 42 consecutive patients who underwent mpMRI, 68Ga-PSMA-11 PET/CT, prostatic biopsy, and radical prostatectomy (RP) was carried out. A lesion-based model (n = 122) using prostatectomy histopathology as reference standard was used to analyze the accuracy of 68Ga-PSMA-11 PET/CT, mpMRI alone, and both in combination to identify ISUP-grade group ≥ 2 lesions. 68Ga-PSMA-11 PET/CT demonstrated greater specificity and positive predictive value (PPV), with values of 73.3% (vs. 40.0%) and 90.1% (vs. 82.2%), while the mpMRI Prostate Imaging Reporting and Data System (PI-RADS) 4–5 had better sensitivity and negative predictive value (NPV): 90.2% (vs. 78.5%) and 57.1% (vs. 52.4%), respectively. When used in combination, the sensitivity, specificity, PPV, and NPV were 74.2%, 83.3%, 93.2%, and 51.0%, respectively. Subgroup analysis of PI-RADS 3, 4, and 5 lesions was carried out. For PI-RADS 3 lesions, 68Ga-PSMA-11 PET/CT demonstrated a NPV of 77.8%. For PI-RADS 4–5 lesions, 68Ga-PSMA-11 PET/CT achieved PPV values of 82.1% and 100%, respectively, with an NPV of 100% in PI-RADS 5 lesions. A combination of 68Ga-PSMA-11 PET/CT and mpMRI improved the radiological diagnosis of csPCa. This suggests that avoidance of prostate biopsy prior to RP may represent a valid option in a selected subgroup of high-risk patients with a high suspicion of csPCa on mpMRI and 68Ga-PSMA-11 PET/CT. Full article
(This article belongs to the Special Issue Advances and Challenges in the Diagnosis and Treatment of Urological Malignancies (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop